Switch theme
Sign up to access all valuation multiples
Laboratorios Farmaceuticos Rovi SA is a biotechnology company engaged in the research, development, manufacturing, and marketing of small molecule and specialty biologic drugs. The company has a diversified portfolio of products that it markets in Spain through its specialized sales force of specialist physicians, hospitals and pharmacies. Laboratorios' research and development pipeline is focused on the expansion of applications, indications, and alternative mechanisms of action for heparin-derived products. The company aims to obtain new pharmaceutical products that enable the regular administration of formulations that are administered daily in chronic and prolonged treatments. Its two segments are Manufacturing and Marketing.
1946
2.0K+
LTM Revenue $807M
LTM EBITDA $214M
$2.8B
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Laboratorios Rovi has a last 12-month revenue of $807M and a last 12-month EBITDA of $214M.
In the most recent fiscal year, Laboratorios Rovi achieved revenue of $820M and an EBITDA of $223M.
Laboratorios Rovi expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Laboratorios Rovi valuation multiples based on analyst estimates| FY 2023 | FY 2024 | FY 2025 | LTM | NTM | |
|---|---|---|---|---|---|
| Revenue | $891M | $820M | XXX | XXX | XXX |
| Gross Profit | $558M | $529M | XXX | XXX | XXX |
| Gross Margin | 63% | 64% | XXX | XXX | XXX |
| EBITDA | $264M | $223M | XXX | XXX | XXX |
| EBITDA Margin | 30% | 27% | XXX | XXX | XXX |
| Net Profit | $214M | $183M | XXX | XXX | XXX |
| Net Margin | 24% | 22% | XXX | XXX | XXX |
| Net Debt | n/a | $22.9M | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of April 15, 2025, Laboratorios Rovi's stock price is EUR 49 (or $53).
Laboratorios Rovi has current market cap of EUR 2.5B (or $2.7B), and EV of EUR 2.6B (or $2.8B).
See Laboratorios Rovi trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $2.8B | $2.7B | XXX | XXX | XXX | XXX | $2.78 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Sign UpAs of April 15, 2025, Laboratorios Rovi has market cap of $2.7B and EV of $2.8B.
Laboratorios Rovi's trades at 3.5x LTM EV/Revenue multiple, and 13.1x LTM EBITDA.
Analysts estimate Laboratorios Rovi's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See valuation multiples for Laboratorios Rovi and 10K+ public comps| FY 2024 | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|
| EV | $2.8B | XXX | XXX | XXX |
| EV/Revenue | 3.4x | XXX | XXX | XXX |
| EV/EBITDA | 12.6x | XXX | XXX | XXX |
| P/E | 18.4x | XXX | XXX | XXX |
| P/E/Growth | 2.0x | XXX | XXX | XXX |
| EV/FCF | 34.3x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Sign UpLaboratorios Rovi's NTM/LTM revenue growth is 1%
Laboratorios Rovi's revenue per employee for the last fiscal year averaged $0.4M, while opex per employee averaged $0.2M for the same period.
Over next 12 months, Laboratorios Rovi's ratio of sales and marketing spend to revenue is estimated to be XXX , while its R&D spend to revenue to be XXX .
Analysts estimate Laboratorios Rovi's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See operational valuation multiples for Laboratorios Rovi and other 10K+ public comps| FY 2024 | NTM | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|---|
| Revenue Growth | -8% | XXX | XXX | XXX | XXX |
| EBITDA Margin | 27% | XXX | XXX | XXX | XXX |
| EBITDA Growth | -15% | XXX | XXX | XXX | XXX |
| Rule of 40 (SaaS-only) | 28% | XXX | XXX | XXX | XXX |
| Revenue per Employee | $0.4M | XXX | XXX | XXX | XXX |
| Opex per Employee | $0.2M | XXX | XXX | XXX | XXX |
| S&M Expenses to Revenue | 3% | XXX | XXX | XXX | XXX |
| G&A Expenses to Revenue | 2% | XXX | XXX | XXX | XXX |
| R&D Expenses to Revenue | n/a | XXX | XXX | XXX | XXX |
| Opex to Revenue | 39% | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Armata Pharmaceuticals | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Laboratorios Rovi acquired XXX companies to date.
Last acquisition by Laboratorios Rovi was XXXXXXXX, XXXXX XXXXX XXXXXX . Laboratorios Rovi acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Sign Up| When was Laboratorios Rovi founded? | Laboratorios Rovi was founded in 1946. |
| Where is Laboratorios Rovi headquartered? | Laboratorios Rovi is headquartered in Spain. |
| How many employees does Laboratorios Rovi have? | As of today, Laboratorios Rovi has 2.0K+ employees. |
| Who is the CEO of Laboratorios Rovi? | Laboratorios Rovi's CEO is Mr. Juan Lopez-Belmonte Encina. |
| Is Laboratorios Rovi publicy listed? | Yes, Laboratorios Rovi is a public company listed on MAD. |
| What is the stock symbol of Laboratorios Rovi? | Laboratorios Rovi trades under ROVI ticker. |
| When did Laboratorios Rovi go public? | Laboratorios Rovi went public in 2007. |
| Who are competitors of Laboratorios Rovi? | Similar companies to Laboratorios Rovi include e.g. Julphar, Galapagos, Pharming, Vivoryon Therapeutics. |
| What is the current market cap of Laboratorios Rovi? | Laboratorios Rovi's current market cap is $2.7B |
| What is the current revenue of Laboratorios Rovi? | Laboratorios Rovi's last 12-month revenue is $807M. |
| What is the current EBITDA of Laboratorios Rovi? | Laboratorios Rovi's last 12-month EBITDA is $214M. |
| What is the current EV/Revenue multiple of Laboratorios Rovi? | Current revenue multiple of Laboratorios Rovi is 3.5x. |
| What is the current EV/EBITDA multiple of Laboratorios Rovi? | Current EBITDA multiple of Laboratorios Rovi is 13.1x. |
| What is the current revenue growth of Laboratorios Rovi? | Laboratorios Rovi revenue growth between 2023 and 2024 was -8%. |
| Is Laboratorios Rovi profitable? | Yes, Laboratorios Rovi is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
